What is the new breakthrough painkiller? A closer look at Journavx
•
3 min read
In a significant advancement for pain management, the FDA approved Journavx™ (suzetrigine) in January 2025, representing a groundbreaking moment in answering the question, "What is the new breakthrough painkiller?". It is the first new non-opioid painkiller of its class to receive approval in over two decades, offering a novel alternative to addictive opioids.
